Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
15 12 2021
15 12 2021
Historique:
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
26
3
2022
Statut:
ppublish
Résumé
HIV programmes world-wide currently make decisions regarding new antiretroviral therapy (ART) regimens with less side-effects and higher resistance barriers, which may improve adherence and viral suppression. Economic evaluation helps inform these decisions. We conducted an economic evaluation of three ART regimens included in the ADVANCE trial from the provider's perspective: tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG) and tenofovir disoproxil fumarate (TDF)/FTC+DTG, compared with TDF/FTC/efavirenz (EFV). We used top-down and bottom-up cost analysis with resource utilization based on trial data and adjusted to emulate routine care. We estimated the cost-effectiveness of each regimen as cost per person virally suppressed or retained and per life-year saved, at 48 and 96 weeks. Though the DTG-based trial arms were 2% more costly than TDF/FTC/EFV, both had slightly lower cost-per-outcome ($9783 and $9929/patient virally suppressed for TDF/FTC+DTG and TAF/FTC+DTG, respectively) than TDF/FTC/EFV ($10 365). The trial cost per additional virally suppressed patient, compared with TDF/FTC/EFV, was lower in the TDF/FTC+DTG arm ($2967) compared with TAF/FTC+DTG ($3430). In routine care, cost per virally suppressed patient was estimated as similar between TDF/FTC+DTG ($426) and TDF/FTC/EFV ($424) but more costly under TAF/FTC+DTG. Similar results were seen in the cost per additional person retained across scenarios. When modelled over 20 years, TDF/FTC+DTG was more cost-effective than TAF/FTC+DTG ($10 341 vs $41 958/life-year saved). TDF/FTC+DTG had similar costs per outcome as TDF/FTC/EFV in the routine care scenario but TDF/FTC+DTG was more cost-effective when modelled over 20 years.
Sections du résumé
BACKGROUND
HIV programmes world-wide currently make decisions regarding new antiretroviral therapy (ART) regimens with less side-effects and higher resistance barriers, which may improve adherence and viral suppression. Economic evaluation helps inform these decisions.
METHODS
We conducted an economic evaluation of three ART regimens included in the ADVANCE trial from the provider's perspective: tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG) and tenofovir disoproxil fumarate (TDF)/FTC+DTG, compared with TDF/FTC/efavirenz (EFV). We used top-down and bottom-up cost analysis with resource utilization based on trial data and adjusted to emulate routine care. We estimated the cost-effectiveness of each regimen as cost per person virally suppressed or retained and per life-year saved, at 48 and 96 weeks.
RESULTS
Though the DTG-based trial arms were 2% more costly than TDF/FTC/EFV, both had slightly lower cost-per-outcome ($9783 and $9929/patient virally suppressed for TDF/FTC+DTG and TAF/FTC+DTG, respectively) than TDF/FTC/EFV ($10 365). The trial cost per additional virally suppressed patient, compared with TDF/FTC/EFV, was lower in the TDF/FTC+DTG arm ($2967) compared with TAF/FTC+DTG ($3430). In routine care, cost per virally suppressed patient was estimated as similar between TDF/FTC+DTG ($426) and TDF/FTC/EFV ($424) but more costly under TAF/FTC+DTG. Similar results were seen in the cost per additional person retained across scenarios. When modelled over 20 years, TDF/FTC+DTG was more cost-effective than TAF/FTC+DTG ($10 341 vs $41 958/life-year saved).
CONCLUSION
TDF/FTC+DTG had similar costs per outcome as TDF/FTC/EFV in the routine care scenario but TDF/FTC+DTG was more cost-effective when modelled over 20 years.
Identifiants
pubmed: 34848584
doi: 10.1097/QAD.0000000000003068
pii: 00002030-202112152-00009
doi:
Substances chimiques
Anti-HIV Agents
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Piperazines
0
Pyridones
0
dolutegravir
DKO1W9H7M1
Emtricitabine
G70B4ETF4S
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
S173-S182Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
UNAIDS Global AIDS Monitoring [Internet]. [cited 2020 Oct 16]. Available at: https://aidsinfo.unaids.org/ Access date 16 Oct 2020.
Raffi F, Pozniak AL, Wainberg MA. Has the time come to abandon efavirenz for first-line antiretroviral therapy? . J Antimicrob Chemother 2014; 69:1742–1747.
Cruciani M, Parisi SG. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: a systematic review and meta-analysis . PLoS One 2019; 14:e0222229.
Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, et al. Icona Foundation Study Group. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort . J Int AIDS Soc 2019; 22:e25227.
Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis . Lancet HIV 2016; 3:e510–e520.
Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection . N Engl J Med 2013; 369:1807–1818.
Wainberg MA, Han Y-S. HIV-1 resistance to dolutegravir: update and new insights . J Virus Erad 2015; 1:13–16.
Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW, et al. Emergent drug resistance with integrase strand transfer inhibitor-based regimens . AIDS 2017; 31:1425–1434.
Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana . N Engl J Med 2019; 381:827–840.
Chouchana L, Pariente A, Pannier E, Tsatsaris V, Treluyer J-M. Dolutegravir and neural tube defects: a new insight . Lancet Infect Dis 2020; 20:405–406.
Shafran SD, Di Perri G, Esser S, Lelièvre J-D, Parczewski M. Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide . HIV Med 2019; 20 Suppl 7:1–16.
DeJesus E, Haas B, Segal-Maurer S, Ramgopal MN, Mills A, Margot N, et al. Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment . AIDS Res Hum Retroviruses 2018; 34:337–342.
Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, noninferiority trial . Lancet HIV 2020; 7:e666–e676.
Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? . AIDS 2018; 32:1551–1561.
South African National Department of Health. 2019 ART clinical guidelines for the management of HIV in adults, pregnancy, adolescents, children, infants and neonates . Pretoria, South Africa: South African National Department of Health; 2019.
Punekar YS, Guo N, Tremblay G, Piercy J, Holbrook T, Young B. Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients . Cost Eff Resour Alloc 2019; 17:26.
Pialoux G, Marcelin A-G, Despiégel N, Espinas C, Cawston H, Finkielsztejn L, et al. Cost-effectiveness of dolutegravir in HIV-1 treatment-experienced (TE) patients in France . PLoS One 2015; 10:e0145885.
Restelli U, Rizzardini G, Antinori A, Lazzarin A, Bonfanti M, Bonfanti P, Croce D. Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients . Ther Clin Risk Manag 2017; 13:787–797.
Pialoux G, Marcelin A-G, Cawston H, Guilmet C, Finkielsztejn L, Laurisse A, Aubin C. Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France . Expert Rev Pharmacoecon Outcomes Res 2018; 18:83–91.
Moreno Guillen S, Losa García JE, Berenguer Berenguer J, Martínez Sesmero JM, Cenoz Gomis S, Graefenhain R, et al. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain . Farm Hosp 2017; 41:601–610.
Zheng A, Kumarasamy N, Huang M, Paltiel AD, Mayer KH, Rewari BB, et al. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India . J Int AIDS Soc 2018; 21:e25085.
Tremblay G, Chounta V, Piercy J, Holbrook T, Garib SA, Bukin EK, Punekar YS. Cost-effectiveness of dolutegravir as a first-line treatment option in the HIV-1-infected treatment-naive patients in Russia . Value Health Reg Issues 2018; 16:74–80.
Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, et al. Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study . Lancet HIV 2018; 5:e146–e154.
Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, et al. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines . Lancet HIV 2020; 7:e193–e200.
Minnery M, Mathabela N, Shubber Z, Mabuza K, Gorgens M, Cheikh N, et al. Opportunities for improved HIV prevention and treatment through budget optimization in Eswatini . PLoS One 2020; 15:e0235664.
Pharmacoeconomic Review Report: Emtricitabine/tenofovir alafenamide (Descovy) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 [cited 2020 Jul 29]. (CADTH Common Drug Reviews). Available at: http://www.ncbi.nlm.nih.gov/books/NBK539225/ Access date 19 July 2020.
Walensky RP, Horn TH, Paltiel AD. The Epi-TAF for tenofovir disoproxil fumarate? . Clin Infect Dis 2016; 62:915–918.
South African Reserve Bank (SARB). Selected historical rates. Repo rate [Internet]. [cited 1 August 2020]. Available at: https://www.resbank.co.za/Research/Rates/Pages/SelectedHistoricalExchangeAndInterestRates.aspx Access date 1 August 2020.
South African Medicine Price Registry. South African National Department of Health. November 2019 [Internet]. 2020. Available at: http://www.mpr.gov.za/ .
Master Procurement Catalogue. South African National Department of Health. December2019 [Internet]. Available at: http://www.health.gov.za/index.php/component/phocadownload/category/196 .
Statistics South Africa. Consumer Price Index History [Internet]. 2020. Available at: http://www.statssa.gov.za/publications/P0141/CPIHistory.pdf ?.
Rand per US Dollar historical exchange rates. South African Reserve Bank [Internet]. Available at: https://www.resbank.co.za/Research/Rates/Pages/SelectedHistoricalExchangeAndInterestRates.aspx Access Date 1 May 2020.
Long L, Girdwood S, Govender K, Lekodeba N, Kgowedi S, Meyer-Rath G, et al. Leveraging private providers to improve and extend HIV treatment access in South Africa: cost implications for universal healthcare in South Africa. AIDS 2020 abstract (A-AIDS2020-02223).
Procurement of laboratory services from the National Health Laboratory Service (NHLS). City of Cape Town Municipality [Internet]. 2019 [cited 2020 May 1]. Available at: http://resource.capetown.gov.za/documentcentre/Documents/Agreements%20and%20contracts/SCMB%2053-10-18.pdf Access Date 1 May 2020.
Johnson LF, May MT, Dorrington RE, Cornell M, Boulle A, Egger M, Davies MA. Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: a mathematical modelling study . PLoS Med 2017; 14:e1002468.
Johnson LF, Dorrington RE. Thembisa version 4.3: a model for evaluating the impact of HIV/AIDS in South Africa. 2019 [Internet]. Available at: www.thembisa.org . Access date 1 May 2020.
Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV . N Engl J Med 2019; 381:803–815.
Eckard AR, McComsey GA. Weight gain and integrase inhibitors . Curr Opin Infect Dis 2020; 33:10–19.
Manne-Goehler J, Baisley K, Vandormael A, Bärnighausen T, Tanser F, Herbst K, et al. BMI and all-cause mortality in a population-based cohort in rural South Africa . Obesity 2020; 28:2414–2423.